FIRST-LINE TREATMENT CHOICE FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS: WHAT DO CLINICIANS CARE ABOUT? THE CLL FITNESS STUDY

被引：0

作者：

Scarfo, L. ^{[1
,2
]}

Quaresmini, G. ^{[3
,4
]}

Ambrosetti, A. ^{[5
]}

Laurenti, L. ^{[6
]}

Rossini, F. ^{[7
,8
]}

Trentin, L. ^{[9
]}

Coscia, M. ^{[10
]}

Orlandi, E. ^{[11
]}

Mannina, D. ^{[12
]}

Torreggiani, A. ^{[13
]}

Rambaldi, A. ^{[3
,4
]}

Semenzato, G. ^{[9
]}

Innocenti, I. ^{[6
]}

Brugiatelli, M. ^{[12
]}

Cuneo, A. ^{[14
]}

Foa, R. ^{[1
,2
,3
,4
]}

Molica, S. ^{[1
,2
,5
]}

Morra, E. ^{[1
,2
,6
]}

Pane, F. ^{[1
,2
,7
,8
]}

Pizzolo, G. ^{[5
]}

Ghia, P. ^{[1
,2
]}

机构：

[1] Ist Sci San Raffaele, Dept Oncohematol, Lymphoma Unit, Milan, Italy

[2] Univ Vita Salute San Raffaele, Milan, Italy

[3] Azienda Osped Papa Giovanni XXIII, Hematol Unit, Bergamo, Italy

[4] Azienda Osped Papa Giovanni XXIII, Bone Marrow Transplant Unit, Bergamo, Italy

[5] Policlin GB Rossi, Dept Hematol, Verona, Italy

[6] Univ Cattolica Sacro Cuore, Inst Hematol, I-00168 Rome, Italy

[7] Osped San Gerardo, Div Ematol, Monza, Italy

[8] Osped San Gerardo, Ctr TMO, Monza, Italy

[9] Univ Padua, Sch Med, Dept Med, Hematol & Clin Immunol Branch, Padua, Italy

[10] Azienda Osped Univ Citta Salute & Sci Torino, Div Hematol, Turin, Italy

[11] Fdn IRCCS Policlin San Matteo, Dept Oncohematol, Hematol Unit, Pavia, Italy

[12] Osped Papardo, Div Ematol, Messina, Italy

[13] Fdn IRCCS Policlin San Matteo, Pavia, Italy

[14] Azienda Osped Univ S Anna, Sect Hematol, Ferrara, Italy

来源：

HAEMATOLOGICA | 2014年 / 99卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

PB1512

引用

页码：587 / 587

页数：1

共 50 条

[21] Outcomes of Conservative Indication Criteria for First-Line Treatment in Chronic Lymphocytic Leukemia: Insights from the Brazilian Registry of CLL
Marques, Fernanda de Morais
Pfister, Verena
Parra, Flavia
Perobelli, Leila
Yamamoto, Mihoko
Buccheri, Valeria
Bandeira de Melo, Raphael Costa
Fortier, Sergio Costa
Santucci, Rodrigo
Bellesso, Marcelo
Ribeiro, Glaciano
Hamerschlak, Nelson
Neto, Abel Costa
Figueiredo, Vera
Fogliatto, Laura Maria
Augusto, Sergio
Lacerda, Marcelo
Goncalves, Matheus Vescovi
Chiattone, Carlos
Arrais-Rodrigues, Celso
BLOOD, 2023, 142
[22] Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): Focus on Long-Term MRD Results
Jain, Nitin
Keating, Michael J.
Thompson, Philip A.
Ferrajoli, Alessandra
Burger, Jan A.
Borthakur, Gautam
Takahashi, Koichi
Estrov, Zeev E.
Sasaki, Koji
Kadia, Tapan M.
Konopleva, Marina
Alvarado, Yesid
Yilmaz, Musa
DiNardo, Courtney D.
Bose, Prithviraj
Ohanian, Maro
Pemmaraju, Naveen
Jabbour, Elias J.
Kanagal-Shamanna, Rashmi
Patel, Keyur
Wang, Wei
Jorgensen, Jeffrey L.
Wang, Sa A.
Garg, Naveen
Wang, Xuemei
Wei, Chongjuan
Cruz, Nichole
Ayala, Ana
Plunkett, William
Kantarjian, Hagop
Gandhi, Varsha
Wierda, William G.
BLOOD, 2021, 138 : 3720 - +
[23] Reasons for initiation of treatment and predictors of response for patients with Rai stage 0/1 chronic lymphocytic leukemia (CLL) receiving first-line therapy: an analysis of the Connect VR CLL cohort study
Flowers, Christopher R.
Nabhan, Chadi
Kay, Neil E.
Mato, Anthony
Lamanna, Nicole
Farber, Charles M.
Davids, Matthew S.
Kiselev, Pavel
Swern, Arlene S.
Sullivan, Kristen
Flick, E. Dawn
Sharman, Jeff P.
LEUKEMIA & LYMPHOMA, 2018, 59 (10) : 2327 - 2335
[24] Prevalence, screening, treatment, and complications of osteoporosis and osteopenia in Medicare patients with chronic lymphocytic leukemia (CLL).lepatients with chronic lymphocytic leukemia (CLL).
Brander, Danielle M.
Oeffinger, Kevin C.
Greiner, Melissa A.
Dinan, Michaela Ann
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[25] Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL)
Al-Sawaf, Othman
Bazeos, Alexandra
Robrecht, Sandra
Bahlo, Jasmin
Gower, Craig
Fink, Anna-Maria
Tresckow, Julia
Cramer, Paula
Langerbeins, Petra
Kutsch, Nadine
Humphrey, Kathryn
Fingerle-Rowson, Guenter
Stilgenbauer, Stephan
Wendtner, Clemens-Martin
Fischer, Kirsten
Eichhorst, Barbara
Hallek, Michael
Goede, Valentin
AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (09) : 1002 - 1006
[26] Real-world treatment patterns in first line and relapsed Chronic Lymphocytic Leukemia (CLL)
Feinberg, Bruce
Schenkel, Brad
McBride, Ali
Ellis, Lorie
Radtchenko, Janna
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 : S204 - S205
[27] Mode of Progression after First Line Treatment Correlates with Outcome of Chronic Lymphocytic Leukemia (CLL)
Al-Sawaf, Othman
Bazeos, Alexandra
Robrecht, Sandra
Bahlo, Jasmin
Fink, Anna Maria
Von Tresckow, Julia
Cramer, Paula
Langerbeins, Petra
Kutsch, Nadine
Humphrey, Kathryn
Fingerle-Rowson, Gunter
Stilgenbauer, Stephan
Wendtner, Clemens-Martin
Fischer, Kirsten
Eichhorst, Barbara F.
Hallek, Michael
Goede, Valentin
BLOOD, 2017, 130
[28] Lenalidomide and Rituximab for the Initial Treatment of Patients with Chronic Lymphocytic Leukemia (CLL) A Multicenter Study of the CLL Research Consortium
James, Danelle F.
Brown, Jennifer R.
Werner, Lillian
Wierda, William G.
Barrientos, Jaqueline C.
Castro, Januario
Greaves, Andrew
Rassenti, Laura Z.
Rai, Kanti R.
Neuberg, Donna
Kipps, Thomas J.
BLOOD, 2011, 118 (21) : 135 - 135
[29] Exercise and Chronic Lymphocytic Leukemia (CLL) - Relationships Among Physical Activity, Fitness, & Inflammation, and Their Impacts on CLL Patients
Sitlinger, Andrea
Thompson, Dana P.
Deal, Michael A.
Garcia, Erwin
Stewart, Tiffany
Guadalupe, Eross
Weinberg, J. Brice
Bartlett, David A.
Brander, Danielle M.
BLOOD, 2018, 132
[30] Chronic lymphocytic Leukemia (CLL) Ibrutinib in the First Line: Standard for High-risk Patients
Pickl, Susanne
ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (1-2) : 76 - 76

← 1 2 3 4 5 →